title: Nicotine abstinence syndrome precipitated by an analog of neuropeptide FF.
abstract: In a recently introduced rodent model of nicotine abstinence syndrome the observed behavioral signs closely resembled those typical of rat opiate abstinence syndrome. Nicotine-induced release of endogenous opioids may contribute to nicotine dependence; morphine potently reverses nicotine abstinence signs, while naloxone precipitates abstinence signs and prevents nicotine from alleviating them. Considerable evidence suggests that neuropeptide FF, an endogenous antiopiate peptide, contributes to opiate dependence. Third ventricle injection of neuropeptide FF precipitates abstinence syndrome in morphine-dependent rats, as does SC injection of its lipophilic analogs, dansyl-PQRFamide and dansyl-RFamide. Might NPFF also play a role in nicotine dependence? In the present study, SC injection of 15 or 25 mg/kg dansyl-RFamide or vehicle alone dose dependently precipitated an abstinence syndrome in nicotine-dependent rats. There was a significant, p < 0.01, positive linear trend of abstinence signs as a function of dose. Categories of abstinence signs had the same rank ordering by frequency as observed in spontaneous nicotine abstinence. Injection of 25 mg/kg dansyl-RFamide SC had no significant effect in nondependent rats.
authors: University of Houston-Clear Lake, TX 77058, USA.
authors: D H
authors: DH
authors: Malin
authors: J R
authors: JR
authors: Lake
authors: P E
authors: PE
authors: Short
authors: J B
authors: JB
authors: Blossman
authors: B A
authors: BA
authors: Lawless
authors: C K
authors: CK
authors: Schopen
authors: E E
authors: EE
authors: Sailer
authors: K
authors: K
authors: Burgess
authors: O B
authors: OB
authors: Wilson
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D007279:Injections, Subcutaneous; D008297:Male; D008969:Molecular Sequence Data; D009292:Narcotic Antagonists / Q000494:pharmacology*; D009479:Neuropeptides / Q000008:administration & dosage / Q000494:pharmacology; D009538:Nicotine / Q000009:adverse effects*; D018722:Nicotinic Agonists / Q000009:adverse effects*; D009842:Oligopeptides / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013375:Substance Withdrawal Syndrome / Q000523:psychology*
chemical_list: D009292:Narcotic Antagonists; D009479:Neuropeptides; D018722:Nicotinic Agonists; D009842:Oligopeptides; C058047:arginylphenylalaninamide; D009538:Nicotine; C053651:phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide